A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
Launched by ELI LILLY AND COMPANY · May 14, 2019
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants must have T2D based on the disease diagnostic criteria World Health Organization (WHO) classification.
- • Participants must have been treated for at least 90 days prior to screening with either basal insulin + at least 1 prandial injection of bolus insulin or premixed analog/human insulin regimens at least twice daily.
- • Participants must be treated no more than 3 oral anti-hyperglycemic medications (OAMs).
- • Participants must have a HbA1c ≥7.0% and ≤11.0%.
- • Participants must have body mass index (BMI) of ≤35.0 kilograms per meter squared (kg/m2).
- Exclusion Criteria:
- • Participants must not have been diagnosed, at any time, with type 1 diabetes (T1D) or latent autoimmune diabetes in adults.
- • Participants must not have had any episode of severe hypoglycemia within the 6 months prior to screening.
- • Participants must not have had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the 6 months prior to screening.
- • Participants must not have used thiazolidinediones, glucagon-like peptide 1 (GLP-1) receptor agonist, or pramlintide within 90 days prior to screening.
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Harbin, Heilongjiang, China
Tianjin, Tianjin, China
Shenyang, Liaoning, China
Fuzhou, Fujian, China
Fuzhou, , China
Luoyang, Henan, China
Cordoba, , Argentina
Changzhou, Jiangsu, China
Siping, Jilin, China
Jinan, Shandong, China
Zhenjiang, Jiangsu, China
Xining, Qinghai, China
Zapopan, Jalisco, Mexico
Shanghai, , China
Monterrey, N.L., Mexico
Beijing, , China
Xingtai, Hebei, China
Pingxiang, , China
Nanjing, Jiangsu, China
Caba, Buenos Aires, Argentina
Changchun, Jilin, China
Guadalajara, Jalisco, Mexico
Buenos Aires, Ar C, Argentina
Beijing, Cn 11, China
Cangzhou, Cn 13, China
Qinhuangdao Shi, Cn 13, China
Hohhot, Cn 15, China
Dalian, Cn 21, China
Shanghai, Cn 31, China
Jiangyin, Cn 32, China
Nanjing, Cn 32, China
Nanjing, Cn 32, China
Nanchang, Cn 36, China
Wuhan, Cn 42, China
Yueyang, Cn 43, China
Chongqing, Cn 50, China
Qiqihar, Heilongjiang, China
Wuhan, Hubei, China
Yichang, Hubei, China
Chenzhou, Hunan, China
Xi 'An, Shanxi, China
San Nicolás De Los Garza, Mx Nle, Mexico
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials